SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

GENETIC TECHNOLOGIES LIMITED(GTG)

Click here for free access to this company's:
ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 FROMTO
GENETIC TECHNOLOGIES LIMITED04/09/2000
DUKETON GOLDFIELDS LIMITED01/11/199904/09/2000
DUKETON GOLDFIELDS NL20/03/199501/11/1999
CONSOLIDATED VICTORIAN MINES NL20/02/199220/03/1995
CONSOLIDATED VICTORIAN GOLD MINES NL22/08/199120/02/1992
CONCORD MINING NL22/08/1991

Shareholder links

Our website ranking of GTG: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare, Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000GTG7
Address: 60-66 Hanover Street, FITZROY, VIC, AUSTRALIA, 3065
Tel:  (03) 8412 7000 Fax: (03) 8412 7040

Date first listed: 30/07/1987
Company Secretary: Justyn Stedwell
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Biotechnology company, pursuing commercial opportunities in the out-licensing of its non-coding patents globally, expanding its genetic service-testing business in the Asia-Pacific Region and supporting certain research projects

News & Events

Expand this box to read and print

OFX Transferring Money Internationally to Free

The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately, following the release by GTG of an announcement regarding a breach of Chapter 10 of the Listing Rules.

06/08/2019

The company provides an operational update on its blockchain activities. In relation to the framework agreement between BCG and GTG, to date, no shares have been issued under the framework agreement and no milestones specified have been achiebed. The share price of GTG needs to reach and remain at a minimum of 2.5c prior to any milestone shares being issued. Any rights to the 486,000,000 milestone shares upon achievement of milestones lapse between 27 December 2019 and 27 June 2020. Also, the Blockshine Health joint venture agreement was terminated on 6 August 2019. Regarding project Shivom which was signed on 2 March 2018, the parties have not progressed further with the undertakings contained in the agreement in recent times. GTG is yet to receive any formal requests for resources or further input or consideration into any blockchain based projects, whether that be via the previous Blockshine Health Joint Venture, BCG or from any other party. As such, GTG intends to remain focused on its core genetic testing business activities and are not currently considering any blockchain related projects. There is no present intention of the Board to change its composition.

06/08/2019

ASX suspended the company for breach of Listing 10.1 and required the company to take corrective action. One form of corrective action was to cancel the transaction. The JV agreement has been terminated effective 6 August 2019. GTG did not receive any formal requests for resources or further input or consideration into any blockchain based projects via the Blockshine Health Joint Venture. As such, GTG has been very focused on its core genetic testing business activities this past calendar year and considers termination of the JV agreement will have no material adverse impact on company operations.

06/08/2019

The securities of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.3, pending an announcement regarding a breach of Chapter 10 of the Listing Rules.

02/08/2019

The securities of Genetic Technologies Limited will be reinstated to quotation immediately, following the release of an announcement by the Company.

15/02/2018

The company has entered into a non-binding terms sheet with Blockchain Global. In addition, in order to secure additional working capital, the Company has also mandated Lodge Corporate Pty Ltd to assist in a proposed private placement of up to 324.7 million new GTG fully paid ordinary shares at an issue price of 0.014c per GTG share.

15/02/2018

The company is presently in discussions with ASX regarding the possible application of ASX Listing Rule 11.1; its structure / operations in compliance with ASX Listing Rule 12.5 and whether a strategic alliance with Blockchain Global Ltd to explore the application of Blockchain technology to provide efficiencies and new opportunities leveraging off the GTG existing genomics business would result in a change of activities of GTG. While these discussions are continuing, the ASX has required that GTG continue in suspension.

12/02/2018

The securities of Genetic Technologies Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

31/01/2018

The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately following the release of an announcement regarding restructuring plans and finalisation of funding. ASX Code: GTG

15/09/2014

The securities of Genetic Technologies Limited (the "Company") will be suspended from quotation immediately at the request of the Company pending the release of an announcement. Security Code: GTG

11/09/2014

securities reinstated

22/07/2011

Genetic Technologies now expects that the capital raising will be finalised on 22 July 2011 (AEST), when a further announcement is expected to be made by the Company in compliance with the ASX listing rules, and at which time the Company expects to recommence trading on both the ASX and NASDAQ

20/07/2011

securities suspended pending an announcement

13/07/2011

Geoffrey Edgar Newing, 44, of Hawthorn East, Victoria, is sentenced to a total of 22 months imprisonment and was ordered to serve six months of this sentence before being released on a recognisance release order

18/03/2010

former Genetic Technologies Limited (GTG) chief operating officer, Geoffrey Edgar Newing, today pleaded guilty to five counts of market manipulation in the Melbourne Magistrates' Court, following an investigation by ASIC - the charges relate to Mr Newing's involvement in the trading of GTG shares between 16 May 2006 and 7 August 2006 - ASIC alleges that during this period Mr Newing took part in transactions involving purchases of more than 2,500,000 GTG shares through a share trading account held in the name of his related company, Palamine Pty Ltd. These transactions, according to ASIC, were likely to create or maintain an artificial price for trading in GTG shares

25/01/2010

name changed from Duketon Goldfields Limited

04/09/2000

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    02/06/2020Nick Burrows1,670,000$0.006$10,020
    02/06/2020Lindsay Wakefield1,092,841$0.006$6,284
    29/05/2020Jerzy Muchnicki38,400,000$0.006$215,040
    29/05/2020Peter Rubenstein60,000,000$0.005$314,960
    13/06/2019Sam Lee-59,594,850$0.012$684,166

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Peter RubensteinChairman31/01/2018
    Jerzy MuchnickiCEO31/01/2018
    Stan SackCOO18/05/2020
    Phillip HainsCFO15/07/2019
    Nick BurrowsNon Exec Director02/09/2019
    Mervyn CassNon Exec Director30/09/2011
    Ian McKenzieNon Exec Director29/11/2013
    Lindsay WakefieldNon Exec Director24/09/2014
    Susan GrossDirector20/06/2016

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Paul KasianChairman, CEO12/12/201324/09/2019
    Paul VineyCFO, COO27/12/201815/07/2019
    Sam LeeNon Exec Director31/01/201809/07/2019
    Kevin FisherCFO02/11/201531/12/2018
    Eutillio BuccilliDirector, CEO02/06/201406/02/2018
    Malcolm BrandonNon Exec Chairman05/10/200930/01/2018
    Grahame LeonardNon Exec Director29/11/201330/01/2018
    Brian ManuelCFO15/06/201502/11/2015
    David CarterNon Exec Director24/09/201429/01/2015
    Alison MewCEO31/08/200931/12/2014
    Tom HowittCFO, Deputy CEO01/06/200428/03/2014
    Tom BonvinoNon Exec Director25/11/200929/11/2013
    Ben SilluzioNon Exec Director10/12/201229/11/2013
    Mel BridgesChairman, Non Exec Director16/12/201127/11/2012
    Paul MacLemanCEO04/05/200927/11/2012
    Gregory BrownNon Exec Director24/07/201227/11/2012
    Huw JonesDirector20/11/200827/11/2012

    Date of first appointment, title may have changed.